

- Necrosis
 caseous, in immune granuloma, 98
 cell death and, 15
 inflammation due to, 72
 ischemic coagulative, 130
 liquefactive, 130
 morphologic changes in, 41-44, 42b, 42f
 patterns of, 43-44
- Necrotizing lesions, of nose and upper airways, 736
- Necrotizing papillitis, 1117b-1119b
- Necrotizing pneumonia, 369b-370b
- Negative selection, in immunologic tolerance, 212-213
- Negri bodies, 1277b, 1277f
- Neisseria gonorrhoeae*, 368
- Neisseria meningitidis*, 368
- Neisserial infections, 368
- Nelson syndrome, 1079-1080
- Nemaline myopathy (NEM), 1240f, 1241t
- Neonatal cholestasis, 856-858, 860b-861b
 major causes of, 857t
- Neonatal hemochromatosis, 849
- Neonatal hepatitis, 856-857, 857f
 morphology of, 857b
- Neonatal jaundice, 853
- Neonatal respiratory distress syndrome, 457-459, 458b, 458f
- Neoplasia, 265-340. *See also* Tumor(s)
 basic components of, 266
 characteristics of benign and malignant, 267-275, 274b-275b, 274t
 differentiation and anaplasia as, 268-271, 269f, 274t
 local invasion as, 271-272, 274t
 metastasis as, 272-275
 clinical aspects of, 329-338, 332b
 defined, 266
 desmoplasia, 266
 host defense, evasion of, 310-314
 antitumor effector mechanisms in, 312
 immune surveillance and escape as, 310, 312-314, 314b
 tumor antigens in, 310-312, 311f
 local and hormonal effects of, 330
 malignant. *See* Cancer
 molecular profiles of, 335-336
 nomenclature for, 266-267, 268t
 scirrhus, 266
 tumor markers for, 337-338, 337t
- Neoplasm, defined, 266
- Neovascular glaucoma, 1328f, 1329
- Neovascularization, 496b-499b
- Nephrin, 900-902, 902f
- Nephritic syndrome, 898, 900t, 909-913
- Nephritis
 hereditary, 924-925, 924f, 925b
 lupus, 926
 tubulointerstitial, 929-930, 929t
 acute *vs.* chronic, 930
 drugs and toxins induced, 935-936, 935b-936b
 due to acute phosphate nephropathy, 937
 due to bile cast nephropathy, 938
 due to hypercalcemia and nephrocalcinosis, 937
 due to light-chain cast nephropathy, 937-938, 937t, 938b, 938f
 due to urate nephropathy, 936-937, 937f
- Nephrocalcinosis, 937
- Nephrogenic adenoma, 963-964
- Nephrolithiasis, 899, 937, 952b, 952f, 1103
- Nephronophthisis, 945f, 948-949, 948b, 949f
- Nephropathy
 associated with NSAIDs, 936
 bile cast, 938
 diabetic, 926
 gouty, 936-937
 light-chain cast, 937-938, 937t, 938b, 938f
 membranous, 910t, 936
 phosphate, acute, 937
 polyomavirus, 933, 933f
 reflux, 934
 sickle-cell, 943
 urate, 936-937, 937f
- Nephrosclerosis, 490b, 938-939, 938b-940b, 939f
 due to diabetes mellitus, 1119f
 malignant, 939-940, 939b-940b, 940f
- Nephrotic syndrome, 898, 900t, 914-923, 922b-923b
 causes of, 914, 915t
 due to focal segmental glomerulosclerosis, 918-920, 919b, 919f
 due to HIV-associated nephropathy, 919-920, 919f
 due to membranoproliferative glomerulonephritis, 920-922, 920b, 920f, 921f
 due to membranous nephropathy, 915-916, 915b, 916f
 due to minimal-change disease, 917-918, 917b, 917f
 pathophysiology of, 914
- Nerve, 1227-1250
- Nesidioblastosis, 1121b
- Neural end organs, in skin, 1142
- Neural tube defects, 1256
- Neuritic plaques, in Alzheimer disease, 1290b-1292b
- Neuroblastic tumors, 475-479
 clinical course and prognostic features of, 477-479, 477t, 478f
 morphology of, 476b-477b
- Neuroblastomas, amplification of NMYC gene in, 289f
- Neuroborreliosis, 1275
- Neurodegenerative diseases, central nervous system, 1286-1301, 1287t-1288t
 Alzheimer disease as, 1287-1292, 1289f, 1291f
 amyotrophic lateral sclerosis as, 1300-1301, 1301f
 ataxia-telangiectasia as, 1299-1300
 atypical parkinsonism syndromes as, 1296
 corticobasal degeneration as, 1296
 dementia with Lewy bodies as, 1295-1296
 Friedreich ataxia as, 1299
 frontotemporal dementia as, 1292
 Huntington disease as, 1297-1298, 1298f
 of motor neurons, 1301
 multiple system atrophy as, 1296-1297
 Parkinson disease as, 1294-1296, 1295f
 Pick disease as, 1292, 1293f
 progressive supranuclear palsy as, 1296
 spinal and bulbar muscular atrophy (Kennedy disease) as, 1301
 spinal muscular atrophy as, 1301
 spinocerebellar, 1298-1300
 vascular (multi-infarct) dementia as, 1268
- Neurofibrillary tangles, 1290b-1292b
- Neurofibromas, 1247
 morphology of, 1247b-1248b
- Neurofibromatosis, 1317
- Neurofibromatosis type 1 (NF1), 298, 1134t, 1156t, 1249
- Neurofibromatosis type 2, 298, 1156t, 1249
- Neurofibromin, 298
- Neurofibromin 2, 298
- Neurokinin A, in inflammation, 89-90
- Neurologic disorder, and systemic lupus erythematosus, 218t
- Neurologic sequelae, of metabolic disturbances, 1304-1305
- Neuromuscular diseases, 1227
- Neuromuscular junction
 antibody-mediated diseases of, 1235-1236
 diseases of, 1235-1237, 1237b
- Neuromyelitis optica (NMO), 1285-1286
- Neuromyopathic paraneoplastic syndromes, 331
- Neurons, 101, 130, 444
 reactions to injury, 1252
- Neuronal degeneration, 1252b-1253b
- Neuronal heterotopias, 1257
- Neuronal inclusions, 1252-1253
- Neuronal injury
 acute, 1252b-1253b
 reactions to, 1252
 subacute and chronic, 1252b-1253b
- Neuronal intracytoplasmic inclusions, 1253
- Neuronal nitric oxide synthase (nNOS), 80
- Neuronal storage diseases, 1302
- Neuronal tumors, of CNS, 1311-1312
- Neuronopathies, 1230
- Neuronophagia, 1253, 1275b
- Neuropathies, metabolic, hormonal, and nutritional, 1232-1233
- Neuropeptides, in inflammation, 89-90
- Neurosyphilis, 379, 380b-381b, 1274, 1275b
- Neurotoxins, 350
- Neutral proteases, 80-81
- Neutropenia, 582-583
 morphology of, 583b
- Neutrophil(s)
 differentiation of, 580f
 in glomerular injury, 907
 in inflammation
 acute, 78
 chronic, 97
 in innate immunity, 187
 in phagocytosis, 79
- Neutrophil extracellular traps (NETs), 81, 81f
- Neutrophilia, in inflammation, 99
- Nevi, conjunctival, 1323
- Nevoid basal cell carcinoma syndrome (NBCCS), 1155-1156, 1156t
- Nevus flammeus, 516
- Nevus of Ota, 1324
- Next-generation sequencing (NGS), 180-182, 181f
- NF1 gene, 298
- NF2 gene, 298, 1249
- Nickel, as carcinogen, 278t
- Nicotinamide adenine dinucleotide (NAD), 418
- Nicotinamide dinucleotide phosphate (NADPH), 1116
- Nicotine, 415
- Niemann-Pick disease type C, 62, 153